Astrazeneca Ab

Jonas Brånalt

David Gustafsson

Marianne Swanson

Magnus Polla

Ingemar Nilsson

Maria Johansson

Anneli Nordqvist

Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X, R, R, R, R, Rand Rare as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides

This invention relates to novel pharmaceutically useful compounds of formula (I), in particular compounds that are competitive inhibitors of trypsin-like serine proteases, especially thrombin, their use as medicaments, pharmaceutical compositions containing them and synthetic routes to their production. 

Compounds 148

Growing community of inventors

Mölndal, Sweden

Jonas Brånalt